Bacillus Subtilis–Derived Exopolysaccharide Halts Depigmentation and Autoimmunity in Vitiligo
Clinical Summary
View sourceWhat was studied
Vitiligo‑prone h3TA2 mice received weekly intraperitoneal injections of Bacillus subtilis–derived exopolysaccharide (EPS) for 18 weeks and were compared with untreated mice; depigmentation was tracked over time and immune responses were measured at the end.
Key findings
EPS significantly slowed depigmentation versus untreated mice. Treated mice had fewer cutaneous CD8+ T cells, more regulatory T cells, more splenic M2 macrophages, higher splenic indoleamine 2,3‑dioxygenase, a shift toward type 2 cytokines, and splenocytes that released less IFN‑γ and other inflammatory cytokines in response to tyrosinase peptide.
Study limitations
Preclinical single‑model mouse study (h3TA2) with intraperitoneal dosing only; immune readouts were collected at endpoint rather than longitudinally; the abstract reports no sample size or quantitative effect sizes for depigmentation.
Related Questions
Explore related topics and deepen your understanding